Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02839876
Other study ID # Pro00072610
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date March 14, 2017
Est. completion date October 31, 2018

Study information

Verified date March 2021
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if intravenous acetaminophen is superior to oral acetaminophen when used as part of a multimodal pathway for primary total hip arthroplasty.


Description:

This is a single center, prospective, randomized controlled study. 60 subjects will be recruited (see #6 Recruitment and Compensation below). On the day of surgery, subjects will be randomized to receive either the study intervention (intravenous acetaminophen and placebo tablets) or the control intervention (intravenous saline and active acetaminophen tablets). The Investigational Drug Service will prepare each intervention package, which will include one intravenous and one oral medication dose. Only one of these routes will be active (determined by randomization). Subjects will receive doses of both an intravenous and oral study drug every 6 hours in order to maintain blinding, and will receive a total of 4 doses of each (at 0, 6, 12 and 18 hours). The dose of acetaminophen in all cases will be 1000 mg. The volume of intravenous acetaminophen (and saline) will be 100 mL. The oral dose will consist of two (2) tablets of 500 mg each (or two matching placebo tablets). All subjects will receive a standardized anesthetic regimen for total hip arthroplasty, as follows: A) Preoperative phase Subjects will receive the following preoperative multimodal drugs: - Pregabalin 75 mg PO - Celecoxib 200 mg PO - The interventional drugs, both IV and PO . The time that these drugs are administered will be recorded as time zero. Patients will then receive a spinal anesthetic with 12.5 mg of isobaric bupivacaine. No peripheral nerve blocks will be performed. B) Intraoperative phase All subjects will be receive propofol infusion beginning at 50 mg/kg/min and titrated to a Richmond Agitation-Sedation Scale score of -1 to -3 (drowsy to moderate sedation). Dexamethasone 10 mg IV and ketamine 0.25 mg/kg IV up to 40 mg total will be administered as part of the standard multimodal regimen. If required, subjects may receive fentanyl 25 mcg IV as needed to treat discomfort. No joint infiltration will be performed by the surgeon. C) Postoperative phase In the Post-Anesthesia Care Unit (PACU), subjects will have an intravenous patient-controlled analgesia (IVPCA) device connected and loading doses of hydromorphone administered by the PACU nurse as necessary (0.2 mg q 8 min prn). On the floor, subjects will receive: - Pregabalin 75 mg PO BID until discharge - Celecoxib 200 mg PO BID until discharge - Dexamethasone 10 mg IV x 1 on postoperative day 1 (24 hours after the first dose) - Intravenous patient-controlled analgesia (IVPCA) with hydromorphone (0.2 mg q 8 min). The remaining 3 intervention packages (IV and PO) will be administered at 6, 12 and 18 hours following the first dose. At time point 24 hours (i.e. the fifth dose of acetaminophen), all subjects will begin to receive 975 mg of oral acetaminophen, continuing every six hours until discharge.


Recruitment information / eligibility

Status Completed
Enrollment 81
Est. completion date October 31, 2018
Est. primary completion date October 2, 2018
Accepts healthy volunteers No
Gender All
Age group 56 Years to 85 Years
Eligibility Inclusion Criteria: - Patients scheduled for elective, primary total hip replacement for osteoarthritis - American Society of Anesthesiologists (ASA) Physical Classification I-III - Weight 50 kg or greater - Body mass index 18-40 kg/m2 Exclusion Criteria: - Inability to consent to study - Inability to speak English - Pregnancy - Weight <50 kg - Revision hip replacement or emergency surgery - Contraindications to spinal anesthesia: coagulopathy or bleeding diathesis, local infection, allergy to local anesthetics - Allergies/intolerances/contraindications to any of the multimodal agents: acetaminophen, pregabalin, celecoxib, ketamine, or dexamethasone - Chronic pain from a separate source other than operative hip - Daily opioid equivalent use of 30 mg of morphine or greater at time of consent - History of heart failure - History of drug or alcohol abuse - Rheumatoid arthritis - Uncontrolled anxiety, schizophrenia or other psychiatric disorder that, in the opinion of the investigator, may interfere with the study assessments - Chronic malnutrition, renal or liver impairment - Hypersensitivity to acetaminophen or any of its excipients

Study Design


Intervention

Drug:
Intravenous acetaminophen
Subject receives 1 g acetaminophen by the intravenous route every 6 hours for 4 doses beginning in the preoperative holding area.
Oral acetaminophen
Subject receives 1 g acetaminophen by the oral route every 6 hours for 4 doses beginning in the preoperative holding area.

Locations

Country Name City State
United States Duke University Hospital Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Hospital Length of Stay Time to both discharge readiness and to actual discharge 0-72 hours
Other Overall Hospital Admission Costs difference in total hospital admission cost between groups 0-72 hours
Other Pharmacy-related Costs difference in pharmacy-related cost between groups 0-72 hours
Other Costs Related to Opioid-related Adverse Events difference in cost related to treatment of opioid-related adverse events (nausea, vomiting, pruritis, constipation, respiratory depression, dizziness) between groups 0-72 hours
Other Cost Associated With Nursing Interventions and Drugs to Treat Opioid-related Adverse Events mean cost (per patient) related to nursing care of opioid-related adverse events (nausea, vomiting, pruritis, constipation, respiratory depression, dizziness) in $USD 0-72 hours
Primary 24 Hour Opioid Consumption Cumulative dose of hydromorphone consumed in the first 24 hours postoperatively 24 hours
Secondary Opioid Consumption (Other) morphine equivalent units of intravenous and oral opioids 0-48 hours
Secondary Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (Preoperatively) Pain scores (using NRS-11 scale) with active range of motion of the hip. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain). preoperatively
Secondary Pain Scores, as Measured by the 11-point Numeric Rating Scale (NRS-11) (1 Hour After Arrival to PACU) Pain scores (using NRS-11 scale) at rest. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain). 1 hour after arrival to PACU
Secondary Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (8 Hours) Pain scores (using NRS-11 scale) at rest. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain). 8 hours
Secondary Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (24 Hours) Pain scores (using NRS-11 scale) at rest. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain). 24 hours
Secondary Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (36 Hours) Pain scores (using NRS-11 scale) at rest. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain). 36 hours
Secondary Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (48 Hours) Pain scores (using NRS-11 scale) at rest. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain). 48 hours
Secondary Subject Satisfaction at 24 Hours Overall subject satisfaction with hospital experience at the 24 hour time point using a simple 11-point Likert scale to quantify global satisfaction. 0=completely unsatisfied, 10=completely satisfied. 24 hours
Secondary Subject Satisfaction at 48 Hours (48 Hours) Overall subject satisfaction with hospital experience at the 48 hour time point using a simple 11-point Likert scale to quantify global satisfaction. 0=completely unsatisfied, 10=completely satisfied. 48 hours
Secondary Straight Leg Raise Number of participants who are able to complete the active straight leg test. The subject rests supine and is asked to lift his/her operative lower limb (with knee extended) until the ankle is 20 cm from level. If the subject can do this, the test is positive. Postoperative day 1
Secondary Heel Slide Test Number of participants who are able to complete the heel-slide test. The subject rests supine and is asked to place the heel of his/her operative side on the contralateral knee, then slide the heel down to the ankle and back in one continuous motion. If the subject can do this, the test is positive. If the subject cannot do this in one motion, or if pain or other factors prevent the test from being performed, the test is negative. Postoperative day 1
Secondary Number of Participants Able to Complete the Supine to Sit Test Number of participants able to go from supine to a sitting position independently. Postoperative day 1
Secondary Self-paced Walk Test Time taken to walk down a hallway 20 m at a safe and quick pace, turn around and return to starting point. Postoperative day 1
Secondary Number of Participants With Opioid-related Adverse Events Incidence of respiratory desaturation events, nausea, vomiting, pruritis, ileus, and constipation 0-72 hours
Secondary Analgesic Consumption as Measured by Patient Diary morphine equivalent units of oral opioids and other non-opioids day 30
Secondary Worst Pain (Day 30) Participants are asked to rate their WORST pain on POSTOPERATIVE DAY 30 on an 11-point scale (0=no pain at all, 10=worst imaginable pain). day 30
Secondary Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (Preoperatively) Pain scores (using NRS-11 scale) at rest. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain). preoperatively
Secondary Pain Scores, as Measured by the 11-point Numeric Rating Scale (NRS-11) (1 Hour After Arrival to PACU) Pain scores (using NRS-11 scale) at with active range of motion of the hip. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain). 1 hour after arrival to PACU
Secondary Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (8 Hours) Pain scores (using NRS-11 scale) with active range of motion of the hip. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain). 8 hours
Secondary Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (24 Hours) Pain scores (using NRS-11 scale) with active range of motion of the hip. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain). 24 hours
Secondary Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (36 Hours) Pain scores (using NRS-11 scale) with active range of motion of the hip. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain). 36 hours
Secondary Subject Satisfaction at 48 Hours Overall subject satisfaction with hospital experience at the 48 hour time point using a simple 11-point Likert scale to quantify global satisfaction. 0=completely unsatisfied, 10=completely satisfied. 48 hours
Secondary Pain Score, as Measured by the 11-point Numeric Rating Scale (NRS-11) (48 Hours) Pain scores (using NRS-11 scale) with active range of motion of the hip. Participants rate their pain on an 11-point scale (0=no pain at all, 10=worst imaginable pain). 48 hours
See also
  Status Clinical Trial Phase
Completed NCT04657926 - A Trial of APPA in the Treatment of Knee Osteoarthritis Phase 2
Completed NCT02536833 - A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects Phase 2
Completed NCT03014037 - Comparing Mesenchymal Stem Cell Counts in Unilateral vs. Bilateral Posterior Superior Iliac Spine Bone Marrow Aspiration N/A
Recruiting NCT05937542 - A Qualitative Investigation of CLEAT Participants
Completed NCT03644615 - A Mindfulness Program (MBSR) in the Management of Symptomatic Hip and Knee Osteoarthritis N/A
Recruiting NCT06061367 - Muscles Strength and Gait Parameteres After TKA
Withdrawn NCT04976972 - A Comparison of Patients Receiving a Total Knee Replacement With Robotic Assistance or With Conventional Instrumentation N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT03850665 - Comparison of Functional Outcome in Patients After Hip Arthroplasty Depending on Surgical Approach N/A
Completed NCT02826902 - Effect of Anesthesia on Quality of Recovery in Patients Undergoing Correctional Tibial Osteotomy - A Randomized Controlled Trial N/A
Completed NCT04402502 - Dynamic 4DCT to Examine Wrist Carpal Mechanics N/A
Completed NCT02923700 - Leukocyte-rich PRP vs Leukocyte-poor PRP for the Treatment of Knee Cartilage Degeneration: a Randomized Controlled Trial Phase 4
Completed NCT04564053 - Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants Phase 1
Completed NCT05070871 - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women N/A
Not yet recruiting NCT05036174 - Diphenhydramine Ointment for Knee Osteoarthritis N/A
Recruiting NCT02912429 - Onlay vs. Inlay Patellofemoral Arthroplasty N/A
Recruiting NCT02666443 - Low Dose Dexamethasone in Supraclavicular Blocks N/A
Active, not recruiting NCT02723929 - Effects of tDCS and tUS on Pain Perception in OA of the Knee
Terminated NCT02820766 - Journey II BCS CMS Total Knee System Compared to Other PS Total Knee Systems in PT Setting N/A
Withdrawn NCT02921594 - Kinematic Comparison of Vanguard XP and Vanguard CR Total Knee Arthroplasties N/A